IP Library Assignment 072667/0827
Patent Assignment
Reel/Frame 072667/0827

Security Interest

Recorded: 2025-10-24 Pages: 13
Assignors
ADVERUM BIOTECHNOLOGIES, INC.
Executed: 2025-10-24
AVALANCHE AUSTRALIA PTY LTD
Executed: 2025-10-24
Assignee
ELI LILLY AND COMPANY
LILLY CORPORATE CENTER, INDIANAPOLIS, INDIANA, 46285
Covered Properties (33)
Compositions and Methods for Intravitreal Delivery of Polynucleotides to Retinal Cones
Application: 17/308,785 →
Publication: US 2021/0388030
Compositions and Methods for Reducing Ocular Neovascularization
Application: 18/046,112 →
Publication: US 2023/0322911
Treatment of Amd Using AAV2 Variant with Aflibercept
Application: 17/479,968 →
Publication: US 2022/0265740
Modified Aav Capsids and Uses Thereof
Application: 18/678,888 →
Publication: US 2024/0301008
Compositions and Methods for Enhanced Gene Expression
Application: 18/307,256 →
Publication: US 2023/0257777
Methods of Treating Ocular Neovascular Diseases Using AAV2 Variants Encoding Aflibercept
Application: 17/017,469 →
Publication: US 2021/0100856
Methods of Treating Ocular Diseases Using AAV2 Variants Encoding Aflibercept
Application: 18/554,965 →
Publication: US 2024/0197915
Melanopsin Variants for Vision Restoration
Application: 18/872,410 →
Method of Reducing Cst Fluctuation in Neovascular Amd by a Recombinant Adeno-Associated Virus
Application: 18/836,648 →
Cassettes of Anti-Complement Component 3 Antibody, Vectorization and Theraputic Application
Application: 18/846,879 →
Methods of Treating Ocular Neovascular Diseases Using AAV2 Variants Encoding Aflibercept
Application: 18/834,864 →
Publication: US 2025/0137011
OPTIMIZATION OF HEK293 SUSPENSION PLATFORM FOR IMPROVED rAAV TITERS
Application: 18/855,209 →
Publication: US 2025/0250547
Compositions and Methods for Treatment of Achromotopsia
Application: 18/879,984 →
Aav Variants for the Treatment of Dry Amd
Application: 19/133,100 →
Immune Landscape Signatures for Ocular Inflammation
Application: 19/472,241 →
rAAV PRODUCTION IN INSECT CELLS
Application: 19/310,594 →
Methods of Treating Ocular Neovascular Diseases Using AAV2 Variants Encoding Aflibercept
Application: 63/721,473 →
Methods of Treating Ocular Neovascular Diseases Using AAV2 Variants Encoding Aflibercept
Application: 63/741,552 →
Treatment of Ocular Neovascularization Using Anti-Vegf Proteins
Application: 17/328,705 →
Publication: US 2022/0111015
Compositions and Methods for Enhanced Gene Expression in Cone Cells
Application: 14/660,657 →
Publication: US 2015/0259395
Compositions and Methods for Enhanced Gene Expression in Cone Cells
Application: 15/984,085 →
Publication: US 2018/0320145
Compositions and Methods for Enhanced Gene Expression in Cone Cells
Application: 17/556,847 →
Publication: US 2022/0259568
Compositions and Methods for Intravitreal Delivery of Polynucleotides to Retinal Cones
Application: 15/554,664 →
Publication: US 2018/0066022
Mutant Viral Capsid Libraries and Related Systems and Methods
Application: 15/388,380 →
Publication: US 2017/0183647
Mutant Viral Capsid Libraries and Related Systems and Methods
Application: 16/750,736 →
Publication: US 2020/0149033
Modified Aav Capsids and Uses Thereof
Application: 15/788,446 →
Publication: US 2018/0127471
Modified Aav Capsids and Uses Thereof
Application: 17/514,711 →
Publication: US 2022/0227816
Compositions and Methods for Enhanced Gene Expression
Application: 16/494,203 →
Publication: US 2020/0010851
Compositions and Methods for Enhanced Gene Expression
Application: 16/998,540 →
Publication: US 2021/0040501
Variant Aav Capsids for Intravitreal Delivery
Application: 16/858,042 →
Publication: US 2020/0338146
Intravitreal Dosing for Delivery of Polynucleotides to Retinal Cones
Application: 17/705,237 →
Publication: US 2023/0062110
Treatment of Ocular Neovascularization Using Anti-Vegf Proteins
Patent: 9,943,573 →
Application: 14/281,749 →
Publication: US 2015/0004101
Treatment of Ocular Neovascularization Using Anti-Vegf Proteins
Application: 15/851,650 →
Publication: US 2018/0125948
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Jul 24, 2015
From: CHALBERG, THOMAS W., JR
To: AVALANCHE BIOTECHNOLOGIES, INC.
Reel/Frame 036174/0164 →
Assignment of Assignor's Interest Jul 24, 2015
From: NEITZ, JAY; NEITZ, MAUREEN
To: UNIVERSITY OF WASHINGTON
Reel/Frame 036174/0169 →
Change of Name Jun 21, 2016
From: AVALANCHE BIOTECHNOLOGIES, INC.
To: ADVERUM BIOTECHNOLOGIES, INC.
Reel/Frame 039113/0225 →
Assignment of Assignor's Interest Feb 27, 2017
From: CHAVEZ, CHRISTOPHER; GASMI, MEHDI; KERAVALA, ANNAHITA
To: ADVERUM BIOTECHNOLOGIES, INC.
Reel/Frame 041388/0187 →
Assignment of Assignor's Interest Dec 11, 2017
From: KERAVALA, ANNAHITA
To: ADVERUM BIOTECHNOLOGIES, INC.
Reel/Frame 044352/0029 →
Assignment of Assignor's Interest Mar 9, 2018
From: NEITZ, JAY; NEITZ, MAUREEN
To: UNIVERSITY OF WASHINGTON
Reel/Frame 045163/0835 →
Assignment of Assignor's Interest May 24, 2018
From: CHALBERG, THOMAS W.
To: ADVERUM BIOTECHNOLOGIES, INC.
Reel/Frame 045895/0071 →
Employee Agreement Apr 30, 2019
From: CHALBERG, THOMAS W.
To: AVALANCHE BIOTECHNOLOGIES, INC.
Reel/Frame 049031/0452 →
Change of Name Apr 30, 2019
From: AVALANCHE BIOTECHNOLOGIES, INC.
To: ADVERUM BIOTECHNOLOGIES, INC.
Reel/Frame 049031/0471 →
Change of Name Feb 3, 2020
From: AVALANCHE BIOTECHNOLOGIES, INC.
To: ADVERUM BIOTECHNOLOGIES, INC.
Reel/Frame 051781/0564 →
Change of Name Feb 3, 2020
From: AVALANCHE BIOTECHNOLOGIES, INC.
To: ADVERUM BIOTECHNOLOGIES, INC.
Reel/Frame 051780/0015 →
Employment Agreement Feb 3, 2020
From: CHALBERG, THOMAS W.
To: AVALANCHE BIOTECHNOLOGIES, INC.
Reel/Frame 051781/0546 →
Assignment of Assignor's Interest Feb 3, 2020
From: CHALBERG, THOMAS W.
To: AVALANCHE BIOTECHNOLOGIES, INC.
Reel/Frame 051701/0596 →
Assignment of Assignor's Interest Feb 3, 2020
From: NEITZ, JAY; NEITZ, MAUREEN
To: UNIVERSITY OF WASHINGTON
Reel/Frame 051701/0624 →
Assignment of Assignor's Interest Feb 3, 2020
From: CHAVEZ, CHRISTOPHER; GASMI, MEHDI; KERAVALA, ANNAHITA
To: ADVERUM BIOTECHNOLOGIES, INC.
Reel/Frame 051702/0687 →
Change of Address Mar 9, 2020
From: ADVERUM BIOTECHNOLOGIES, INC.
To: ADVERUM BIOTECHNOLOGIES, INC.
Reel/Frame 052808/0698 →
Assignment of Assignor's Interest Jan 29, 2021
From: GASMI, MEHDI; KISS, SZILARD; OSBORNE, AARON; TURPCU, ADAM
To: ADVERUM BIOTECHNOLOGIES, INC.
Reel/Frame 055085/0511 →
Assignment of Assignor's Interest Jun 10, 2021
From: NEITZ, JAY; NEITZ, MAUREEN
To: UNIVERSITY OF WASHINGTON
Reel/Frame 056500/0540 →
Assignment of Assignor's Interest Jun 10, 2021
From: CHALBERG, THOMAS W., JR.
To: ADVERUM BIOTECHNOLOGIES, INC.
Reel/Frame 056500/0536 →
Assignment of Assignor's Interest Sep 29, 2022
From: BLUMENKRANZ, MARK; GASMI, MEHDI
To: ADVERUM BIOTECHNOLOGIES, INC.
Reel/Frame 061253/0842 →
Change of Name Dec 5, 2022
From: AVALANCHE BIOTECHNOLOGIES, INC.
To: ADVERUM BIOTECHNOLOGIES, INC.
Reel/Frame 062064/0632 →
Assignment of Assignor's Interest Dec 5, 2022
From: NEITZ, JAY; NEITZ, MAUREEN
To: UNIVERSITY OF WASHINGTON
Reel/Frame 061979/0989 →
Assignment of Assignor's Interest Dec 5, 2022
From: CONSTABLE, IAN J.; RAKOCZY, P. ELIZABETH; LAI, CHOOI-MAY
To: LIONS EYE INSTITUTE LIMITED
Reel/Frame 061979/0257 →
Assignment of Assignor's Interest Dec 5, 2022
From: CHALBERG, THOMAS W., JR.
To: AVALANCHE AUSTRALIA PTY LTD.
Reel/Frame 061979/0376 →
Assignment of Assignor's Interest Dec 5, 2022
From: LIONS EYE INSTITUTE LIMITED
To: AVALANCHE AUSTRALIA PTY LTD.
Reel/Frame 061979/0448 →